Covid-19 vaccine received a fast-track designation from U.S. regulators as the drugmaker prepares to launch a large, late-stage study before the end of the month, the company said on Monday.The expedited review by the U.S.
Food and Drug Administration could help place the company’s candidate among a short-list of frontrunners in the race to bring a vaccine to market.Some of the most high-profile vaccines are moving closer to approval.
Also Monday, Pfizer Inc. and BioNTech SE reported preliminary results showing their vaccine candidate was 90% effective in a late-stage trial.